Breaking the Steroid Cycle: Elevating Long-Term Care in Pediatric Atopic Dermatitis With PDE4 Inhibition
Please check back later for more content.
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Data Position Zasocitinib as a Potential New Oral Option for Psoriasis
2
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
3
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
4
FDA Clears IND Application of Recludix’s Oral STAT6, REX-8756
5